Skip to main content
Premium Trial:

Request an Annual Quote

Response Genetics' Q4 Revenues Increase 134 Percent on PGx Test Sales

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Response Genetics has reported a 134 percent increase in its fourth-quarter revenues, driven by sales of its ResponseDx line of pharmacogenomic tests.

The Los Angeles-based firm brought in total revenues of $3.4 million for the three-month period ended Dec. 31 compared to $1.4 million for the fourth quarter of 2008. The company cited a ramp up in sales of its ResponseDx tests, with revenues growing 81 percent compared to the third quarter of 2009.

Response Genetics' net loss for the quarter was halved to $1.7 million, or $.11 per share, from $3.4 million, or $.33 per share.

Its R&D spending increased to $559,080 from $433,044 year over year, and its SG&A spending increased to $2.7 million from $2.2 million.

For full-year 2009, Response Genetics' sales rose 28 percent to $9.1 million from $7.1 million.

Its net loss dropped to $9.3 million, or $.70 per share, from $9.5 million, or $.93 per share. The firm's R&D expenses increased to $2.3 million from $2.1 million, while its SG&A spending jumped to $9.7 million from $7.5 million.

Response Genetics finished the year with cash and cash equivalents of $7.1 million.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.